TriSalus Life Sciences (TLSI) Cost of Revenue (2022 - 2026)

TriSalus Life Sciences (TLSI) has 5 years of Cost of Revenue data on file, last reported at $7.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 395.85% year-over-year to $7.4 million; the trailing twelve-month figure through Mar 2026 stood at $12.9 million (down 16.95% YoY), and the FY2025 full-year result was $7.0 million, down 73.04% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.4 million, up from $1.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $7.4 million in Q1 2026 and bottomed at -$6.6 million in Q4 2022.
• The 5-year median for Cost of Revenue is $1.5 million (2025), against an average of $1.9 million.
• The widest annual swing landed in 2023, when Cost of Revenue slumped 80.56%; it then surged 1104.47% in 2024.
• A 5-year view of Cost of Revenue shows it stood at -$6.6 million in 2022, then jumped by 108.79% to $582000.0 in 2023, then soared by 1104.47% to $7.0 million in 2024, then sank by 74.86% to $1.8 million in 2025, then soared by 320.72% to $7.4 million in 2026.
• The last three Cost of Revenue figures came in at $7.4 million (Q1 2026), $1.8 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison